Intellectual property related to the Australian Life Sciences sector

Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (31 December 2017)

The World Intellectual Property Organisation publishes new PCT patent applications every Thursday. Australian applicants generally have 12 or 13 healthcare and biotech-related patent applications published each month while New Zealand applicants have two or three a month.

Australian applications

Here are the 165 PCT patent applications relevant to Australia's Life Sciences sector that published in 2017, for a publication rate of 3.2 applications per week:

WO/2017/221158, Anti-parasitic compositions and methods, University of Canberra, 28 December 2017
WO/2017/220369, Antibodies against MAC-1, Baker IDI Heart and Diabetes Institute and Albert-Ludwigs-Universität Freiburg, 28 December 2017
WO/2017/219087, New thiosemicarbazone compounds and analogues thereof, University of Sydney, 28 December 2017
WO/2017/219086, Anti-ageing compounds, University of Sydney, 28 December 2017
WO/2017/219083, Activators of HIV latency, University of Melbourne and Walter and Eliza Hall Institute of Medical Research, 28 December 2017
WO/2017/219081, Spider venom peptides and methods of use for modulating sodium channels, University of Queensland, 28 December 2017
WO/2017/219080, Treatment for myopia, University of Newcastle, 28 December 2017
WO/2017/219078, Allosteric regulation of haemostatic activity, University of Sydney, 28 December 2017
WO/2017/214683, Methods and compositions for the treatment or prophylaxis of an ectoparasitic infestation, Gretals Australia Pty Ltd, 21 December 2017
WO/2017/214681, Agents and methods for the diagnosis and treatment of diseases associated with extracellular matrix turnover, Baker IDI Heart and Diabetes Institute, 21 December 2017
WO/2017/214680, Adamantane compounds, University of Sydney, 21 December 2017
WO/2017/210749, Methods and products for treating autoimmune diseases, University of Adelaide, 14 December 2017
WO/2017/210735, Methods of treating neuroblastoma and reagents therefor, Garvan Institute of Medical Research, 14 December 2017
WO/2017/210726, Peptides for hair growth, Clinical Stem Cells Pty Ltd, 14 December 2017
WO/2017/205939, Vitamin D formulations and therapeutic uses thereof, Indigo Ridge Pty Ltd, 7 December 2017
WO/2017/205901, Hydrophilic polymer conjugate with multiple antiviral agents for treating a viral infection, Commonwealth Scientific and Industrial Research Organisation, 7 December 2017
WO/2017/205895, Skin care formulation, Embryogenesis Pty Ltd, 7 December 2017
WO/2017/203397, Inner ear plug, Cochlear Ltd, 30 November 2017
WO/2017/203368, Methods of treating autoimmune disease using allogeneic T cells, QIMR Berghofer Medical Research Institute, 30 November 2017
WO/2017/203362, Immune checkpoint inhibitors and cytotoxic T cells for the treatment of cancer, QIMR Berghofer Medical Research Institute, 30 November 2017
WO/2017/201585, Modulators of DUX4 for regulation of muscle function, Genea Biocells, 30 November 2017
WO/2017/201581, Non-toxic iron chelators with neuroprotective potential, University of Sydney, 30 November 2017
WO/2017/201579, Arthrogenic alphavirus vaccine, Griffith University, 30 November 2017
WO/2017/201573, A method of classification and treatment, Peter MacCallum Cancer Institute, 30 November 2017
WO/2017/201563, Treatment of alphavirus-induced inflammation, Griffith University, 30 November 2017
WO/2017/197463, Treatment of pain, Monash University and Queens University at Kingston (Canada), 23 November 2017
WO/2017/197453, Microencapsulated omega-3 polyunsaturated fatty acid glyceride compositions and processes for preparing the same, Deakin University, 23 November 2017
WO/2017/194912, Treatment of complement-mediated disorders, University of Cambridge (UK) and Sydney Children's Hospital Network, 16 November 2017
WO/2017/193169, Protection of plant extracts and compounds from degradation, Medlab Clinical Ltd, 16 November 2017
WO/2017/193161, Agent delivery system, WRS Therapeutics Pty Ltd, 16 November 2017
WO/2017/192699, Adeno-Associated Virus polynucleotides, polypeptides and virions, Children's Medical Research Institute, Sydney Children's Hospital Network and US Department of Health and Human Services, 9 November 2017
WO/2017/190197, Reagents for treatment of Hepatitis B Virus (HBV) infection and use thereof, Benitec Biopharma Ltd, 9 November 2017
WO/2017/190193, Method of prophylaxis of Zika virus infection, Starpharma Ltd, 9 November 2017
WO/2017/190183, Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith, T & A Pharma Pty Ltd, 9 November 2017
WO/2017/185142, Method for preventing and/or treating atrial fibrillation, University of Adelaide, 2 November 2017
WO/2017/185123, Veterinary composition, Alan Thompson, 2 November 2017
WO/2017/181245, Method of treating inflammation and promoting wound healing, Sang Pacific Enterprises Pty Ltd, 26 October 2017
WO/2017/181243, Method of treating or preventing liver conditions, CSL Ltd and B-Creative Sweden AB, 26 October 2017
WO/2017/181242, Chemotherapy improvements, Noxopharm, 26 October 2017
WO/2017/177283, Methods of manufacturing nutritional formulations, Clover Corporation Ltd, 19 October 2017
WO/2017/177277, Reagents for treatment of Oculopharyngeal Muscular Dystrophy (OPMD) and use thereof, Benitec Biopharma Ltd, 19 October 2017
WO/2017/177270, Composition of proenzymes for cancer treatment, Propanc Biopharma, 19 October 2017
WO/2017/177265, Injectable composition for delivery of a biologically active agent, Capsular Technologies Pty Ltd, 19 October 2017
WO/2017/177262, Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier, University of Canberra, 19 October 2017
WO/2017/177261, Liposomal preparation and methods of treatment, Habi Pharma Pty Ltd, 19 October 2017
WO/2017/176403, Method and composition for dag mitigation on hair, Empire Technology Development LLC, 12 October 2017
WO/2017/173498, Isoflavonoid composition with improved pharmacokinetics, Noxopharm, 12 October 2017
WO/2017/173497, Targeted drug delivery, Noxopharm, 12 October 2017
WO/2017/173496, Radiotherapy improvements, Noxopharm, 12 October 2017
WO/2017/173494, Method of treating atherosclerosis, CSL Ltd, 12 October 2017
WO/2017/173487, Nanofibrous mat containing ceramic particles with releasable dopant, SG Ventures Pty Ltd and Nanopharma a.s. (Czechia)
WO/2017/173478, Acoustic wave mediated non-invasive drug delivery, Mupharma Pty Ltd, 12 October 2017
WO/2017/173474, Improvements in cancer treatment, Noxopharm, 12 October 2017
WO/2017/165908, Method of inhibiting high fat diet-related conditions, South Australian Health and Medical Research Institute and Ocean University of China (China), 5 October 2017
WO/2017/161414, Administration of an anti- LGR5 monoclonal antibody, Bionomics Ltd, 28 September 2017
WO/2017/161408, Dental adhesive compositions, SDI Ltd, 28 September 2017
WO/2017/161402, Formulation and method for the prevention and/or treatment of hangover symptoms, Phoenix Pharmaceuticals Australia Pty Ltd, 28 September 2017
WO/2017/160587, Neutralizing monoclonal antibodies to Il-25 and uses thereof, Abeome Corporation (US) with Nathan Bartlett and others
WO/2017/156591, Osteoarthritis miRNAs, Murdoch Childrens Research Institute and University of Sydney, 21 September 2017
WO/2017/156580, Colony forming medium and use thereof, Cynata Therapeutics, 21 September 2017
WO/2017/153521, Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 14 September 2017
WO/2017/153520, Benzopiperidine derivatives and their use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 4 September 2017
WO/2017/153519, 3-oxa-8-azabicyclo[3.2.1]octane derivatives and thier use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 14 September 2017
017/153519, 3-oxa-8-azabicyclo[3.2.1]octane derivatives and thier use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 14 September 2017
WO/2017/153518, PRMT5 inhibitors, CTxT Pty Ltd, 14 September 2017
WO/2017/153515, Tetrahydroisoquinolines as PRMT5 inhibitors, CTxT Pty Ltd, 14 September 2017
WO/2017/153513, Tetrahydroisoquinolines as PRMT5 inhibitors, CTxT Pty Ltd, 14 September 2017
WO/2017/152237, Novel analogues of Desferrioxamine B (DFOB), University of Sydney, 14 September 2017
WO/2017/147654, Use of phosphorylated tau and p38gamma to treat a neurological condition, University of New South Wales, 8 September 2017
WO/2017/147653, Methods of treating bone diseases, disorders and/or injuries and reagents therefor, Cellmid Ltd, 8 September 2017
WO/2017/147649, Methods of treatment, Magellan Stem Cells Pty Ltd, 8 September 2017
WO/2017/143406, Multi-specific molecules, Imunexus Pty Ltd, 31 August 2017
WO/2017/143397, Inhibitors of β-arrestin-neurokinin 1 receptor interactions for the treatment of pain, Monash University, 31 August 2017
WO/2017/142825, N3-substituted iminopyrimidinones as antimalarial agents, Merck & Co. (US) with Walter and Eliza Hall Institute of Medical Research, 24 August 2017
WO/2017/142821, Compounds for the treatment of malaria, Merck & Co. (US) with Walter and Eliza Hall Institute of Medical Research, 24 August 2017
WO/2017/139854, Compositions and methods for the treatment of sinus disease and disorders, ENT Technologies Pty Ltd, 24 August 2017
WO/2017/139849, Anti-virus agent and method for treatment of viral infection, Recce Ltd, 24 August 2017
WO/2017/139846, Formulation and method of use, ATP Institute Pty Ltd, 24 August 2017
WO/2017/139845, Novel alpha conotoxin peptides, University of Queensland, 24 August 2017
WO/2017/139290, Tralokinumab delivery device, Medimmune (US) and Unilife, 17 August 2017
WO/2017/136871, Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof, Pharmaxis Ltd, 17 August 2017
WO/2017/136870, Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof, Pharmaxis Ltd, 17 August 2017
WO/2017/132728, Proteinaceous compounds and uses therefor, University of Canberra, 10 August 2017
WO/2017/127892, Cancer treatment, Propanc Biopharma, 3 August 2017
WO/2017/124156, Compositions that brighten skin, provide sun protection, and permit Vitamin D production, Ernest Armstong, 27 July 2017
WO/2017/124147, Novel biomolecule conjugates and uses therefor, University of Western Australia and Sanford Burnham Prebys Medical Discovery Institute (US), 27 July 2017
WO/2017/117631, Mutated truncated von Willebrand factor, CSL Ltd, 13 July 2017
WO/2017/117630, Mutated von Willebrand factor, CSL Ltd, 13 July 2017
WO/2017/117627, Drug release device and use, Jurox Pty Ltd, 13 July 2017
WO/2017/112792, Tripartite modulators of endosomal G Protein-Coupled Receptors, Takeda Pharmaceutical Company (Japan) with two Monash University scientists, among others, 29 June 2017
WO/2017/106930, Compounds, Commonwealth Scientific and Industrial Research Organisation, 29 June 2017
WO/2017/106926, Nucleic acid oligomers and uses therefor, Queensland University of Technology, 29 June 2017
WO/2017/106899, Therapeutic methods using erythrocytes, Sangui Bio Pty Ltd, 29 June 2017
WO/2017/100863, Injectable composition and a method of treatment of the physical addiction, Verita Research Pte Ltd, 22 June 2017
WO/2017/100861, Inhibition of cytokine-induced SH2 protein in NK cells, Walter and Eliza Hall Institute of Medical Research, 22 June 2017
WO/2017/100860, Exfoliant bar, DPP Pharmaceuticals Pty Ltd, 22 June 2017
WO/2017/100858, Polymer composite for controlled release of an agent, Commonwealth Scientific and Industrial Research Organisation, 22 June 2017
WO/2017/100849, 6-oxopurine phosphoribosyl transferase inhibitors, University of Queensland and Institute of Organic Chemistry and Biochemistry (Czechia), 22 June 2017
WO/2017/100825, A pharmaceutical composition and uses therefor, Robert Gilligan and Wayne Daley, 22 June 2017
WO/2017/100819, Modular syntheses of discoipyrrole type alkaloids and analogues, Australian National University, 22 June 2017
WO/2017/096432, Immunomodulating composition for treatment, Admedus, 15 June 2017
WO/2017/096431, Proteinaceous molecules and methods of use, University of Queensland, Florey Institute of Neuroscience and Mental Health, Johns Hopkins University (US) and the University of California (US), 15 June 2017
WO/2017/096430, Hydroxamic acid-based compounds, University of Sydney, 15 June 2017
WO/2017/096427, Pharmaceutical formulation, Phosphagenics Ltd, 15 June 2017
WO/2017/096426, Methods and compositions for treating gastric ulcers, Luoda Pharma Pty Ltd, 15 June 2017
WO/2017/093807, Methods of treating or alleviating mental disorders and associated symptoms, Florey Institute of Neuroscience and Mental Health and Deakin University, 8 June 2017
WO/2017/091866, Regulation of cytokine production, Commonwealth Scientific and Industrial Research Organisation, 8 June 2017
WO/2017/091850, Novel anti-angiogenic fusion polypeptides, Pieris Pharmaceuticals, 8 June 2017
WO/2017/088031, Photostable compounds, absorbing compounds and uses thereof, Commonwealth Scientific and Industrial Research Organisation, 1 June 2017
WO/2017/088028, CD131 binding proteins and uses thereof, CSL Ltd, 1 June 2017
WO/2017/088027, Inhibin analogs, Hudson Institute of Medical Research, 1 June 2017
WO/2017/088018, Production of viruses in cell culture, Commonwealth Scientific and Industrial Research Organisation and University of Georgia (US), 1 June 2017
WO/2017/088012, Genetically modified cells and uses thereof, Cartherics Pty Ltd, 1 June 2017
WO/2017/083938, Method of controlled competitive exchange, Anteo Diagnostics Ltd, 26 May 2017
WO/2017/083931, A non-surgical vulvovaginal rejuvenation technique and an injecting device therefor, Abbas Al-Taiff, 26 May 2017
WO/2017/083925, Compounds and methods for treating metabolic disorders, Garvan Institute of Medical Research, 26 May 2017
WO/2017/083914, Compounds for medicinal applications, Australian Biomedical Co. Pty Ltd, 26 May 2017
WO/2017/079802, Proenzyme composition, Propanc Biopharma, 18 May 2017
WO/2017/078928, FXR agonists and methods for making and using, Salk Institute for Biological Studies (US) and University of Sydney, 11 May 2017
WO/2017/078927, Analogs of fexaramine and methods of making and using, Salk Institute for Biological Studies (US) and University of Sydney, 11 May 2017
WO/2017/075672, Method and product for testing response to oral glucose load, INR Enterprises Pty Ltd, 11 May 2017
WO/2017/075670, Mobilizing leukemia cells, Children's Hospital Los Angeles (US) and Antisense Therapeutics, 11 May 2017
WO/2017/075661, Methods and compositions for treating CNS injury, Monash University, 11 May 2017
WO/2017/075653, Chlamydia antigens and uses thereof, University of the Sunshine Coast, 11 May 2017
WO/2017/070752, Imaging agents, University of Queensland, 4 May 2017
WO/2017/070744, Methods and compositions for improving glucose metabolism, Monash University, 4 May 2017
WO/2017/070738, A method of treatment and agents useful for same, University of Queensland and QIMR Berghofer Medical Research Institute, 4 May 2017
WO/2017/070735, Liposomal vaccine, Griffith University, 4 May 2017
WO/2017/070731, Compositions and methods for the treatment of Alzheimer's disease, Innate Immunotherapeutics Ltd, 4 May 2017
WO/2017/066827, Methods of reducing mammographic breast density and/or breast cancer risk, Havah Therapeutics Pty Ltd, 27 April 2017
WO/2017/063023, Compositions and methods for the treatment of diseases involving mucin, University of New South Wales, 20 April 2017
WO/2017/063017, Treatment or prevention of giardiasis with a biologically active extract from Terminalia ferdinandiana fruit, Gunaguddya Pty Ltd, 20 April 2017
WO/2017/059486, Compositions and methods for the treatment of epilepsy, Innate Immunotherapeutics Ltd, 13 April 2017
WO/2017/059485, Compositions and methods for protection and/or repair of the nervous system, Innate Immunotherapeutics Ltd, 13 April 2017
WO/2017/059319, Combination therapy of bromodomain inhibitors and checkpoint blockade, Dana-Farber Cancer Institute (US) and Peter MacCallum Cancer Institute, 6 April 2017
WO/2017/054047, Antimicrobial polymyxin derivative compounds, Monash University, 6 April 2017
WO/2017/054042, Novel formulation and treatment methods, University of Queensland, 6 April 2017
WO/2017/049349, A method of treatment and prophylaxis, Hudson Institute of Medical Research, 30 March 2017
WO/2017/045034, Ubiquinone and ubiquinol compositions, and methods relating thereto, Pharmako Biotechnologies Pty Ltd, 23 March 2017
WO/2017/045019, Antibiotic therapy, Boulos & Cooper Pharmaceuticals Pty Ltd, 23 March 2017
WO/2017/041142, Polymer conjugate comprising a bioactive agent, Polyactiva Pty Ltd, 16 March 2017
WO/2017/041139, Lymph directing prodrugs, Monash University, 16 March 2017
WO/2017/041133, Cell expansion methods and therapeutic compositions, Cell Ideas Pty Ltd, 16 March 2017
WO/2017/035595, Formation of bone, Elastagen Pty Ltd, 9 March 2017
WO/2017/035587, Bioactive polymer for bone regeneration, University of Sydney, 9 March 2017
WO/2017/035582, Methods and products for preventing and/or treating microorganism infections comprising iron chelators and non-iron porphyrins, University of Adelaide, 9 March 2017
WO/2017/035566, Plasma polymerised oxazoline coatings and uses thereof, University of South Australia, 9 March 2017
WO/2017/031299, Enzymatic fractions with anti-inflammatory activity, Anatara Lifesciences Ltd, 23 February 2017
WO/2017/030901, Mycoplasma bovis compositions, Zoetis (US) and University of Melbourne, 23 February 2017
WO/2017/027910, Connexin 45 inhibition for therapy, University of Sydney and Western Sydney Local Health District, 23 February 2017
WO/2017/027898, Novel cancer treatment involving modulation of Il-3 activity, University of South Australia and Central Adelaide Local Health Network, 23 February 2017
WO/2017/025635, Composition for the treatment of joint conditions, Newven SPRL (Ransart, Belgium) and four inventors including Simon Humphrys of Adelaide, 16 February 2017
WO/2017/024355, Compositions comprising S1P receptor modulators, Akaal Pharma Pty Ltd, 16 February 2017
WO/2017/020094, Methods for treating tumours, Centenary Institute of Cancer Medicine and Cell Biology, Mirrx Therapeutics A/S and University of Sydney, 9 February 2017
WO/2017/020087, Emollient composition, Eupharma Pty Ltd, 9 February 2017
WO/2017/020086, Benzodiazepines as bromodomain inhibitors, Catalyst Therapeutics Pty Ltd, 9 February 2017
WO/2017/020065, n-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds, University of South Australia, 9 February 2017
WO/2017/017511, Modified release formulation for treating premature ejaculation, Selim Kameel, 2 February 2017
WO/2017/015722, Complexes for intracellular imaging, University of South Australia and Curtin University of Technology, 2 February 2017
WO/2017/015720, Fibrotic treatment, Monash University, 2 February 2017
WO/2017/015703, Antiseptic polymer and synthesis thereof, University of Sydney, 2 February 2017
WO/2017/011863, Neuroprotective agents derived from spider venom peptides, University of Queensland and Monash University, 26 January 2017
WO/2017/008101, Novel aminopeptidase inhibitors and methods of use, Monash University, 19 January 2017
WO/2017/004678, Cross-reactive antifungal adoptive T cell therapy, University of Sydney and Western Sydney Local Health District, 12 January 2017
WO/2017/004674, Therapeutic compounds and compositions for treating social disorders and substance use disorders, University of Sydney, 12 January 2017
WO/2017/004672, Peptidyl TPOR antagonists and uses thereof, Polymers CRC Ltd, 12 January 2017

New Zealand applications

Here are the 24 PCT patent applications relevant to New Zealand's Life Sciences sector that published in 2017, for a publication rate of 0.5 applications per week:

WO/2017/217868, Water-dispersible propolis composition, Andrew Lavrent, 21 December 2017
WO/2017/213524, Treatment of neurodegenerative disorders, Garth Cooper, 14 December 2017
WO/2017/200396, Antibacterial compositions, David Ackerley and Janine Copp, 23 November 2017
WO/2017/200391, Compositions comprising L-Theanine, proanthocyanidin/s and a catechin and uses thereof, Alphagen NZ, 23 November 2017
WO/2017/192620, Novel peptides and peptidomimetics, University of Auckland and Ocunexus Therapeutics, 9 November 2017
WO/2017/183996, Combination,therapeutic uses and prophylactic uses, Quantec Ltd, 26 October 2017
WO/2017/179996, Collagen-based device having antifungal properties, Aroa Biosurgery, 19 October 2017
WO/2017/171563, Beta-caseins and cognitive function, A2 Milk Company, 5 October 2017
WO/2017/164750, Therapeutic compositions and uses thereof, Manuka Health New Zealand Ltd, 28 September 2017
WO/2017/153943, Topical composition, Biopharm NZ Ltd, 14 September 2017
WO/2017/142424, Treatment of neurodegenerative disorders, Garth Cooper, 24 August 2017
WO/2017/131534, Treatment of vascular anomalies, Gillies McIndoe Research Institute, 3 August 2017
WO/2017/111618, Infant formula comprising human milk peptides, A2 Milk Company Ltd, 29 June 2017
WO/2017/099612, Marker compounds of Leptospermum honeys and methods of isolation and assaying thereof, Comvita Ltd, 15 June 2017
WO/2017/095237, Carbon monoxide releasing norbornenone compounds, Ivan Sammut et. al., 8 June 2017
WO/2017/082753, Glycolipid compounds and their uses in the treatment of tumours, Agalimmune Ltd (UK) with Kode Biotech, 18 May 2017
WO/2017/078544, Nutrient loss reduction method, PGG Wrightson Seeds Ltd, 11 May 2017
WO/2017/074262, Core-shell composite material, Agency for Science, Technology and Research (Singapore) with Massey University and AgResearch, 4 May 2017
WO/2017/065619, Nitrogen utilisation modulation, PGG Wrightson Seeds Ltd, 20 April 2017
WO/2017/061878, Antimicrobial gel containing silver nanoparticles, Carla Meledandri, 13 April 2017
WO/2017/034420, Inhibitors of Tryptophan Dioxygenases (IDO1 and TDO) and their use in therapy, Auckland Uniservices Ltd, 2 March 2017
WO/2017/034418, Acoustic driven drug delivery systems, John Reynolds, 2 March 2017
WO/2017/018889, Manuka and/or kanuka honey wet wipes and manuka and/or kanuka oil tissues, Imbue NZ Ltd, 2 February 2017
WO/2017/003305, Peptides and uses thereof, Auckland Uniservices Ltd, 5 January 2017